In pharmaceutical research and development, Palm Oil Oleic Acid 7070 exhibits various potential effects. It can effectively regulate body metabolism and influence inflammatory markers and the PPAR metabolic pathway, thereby showing certain anti-inflammatory effects, which holds application potential in the treatment and prevention of inflammatory-related diseases. Relevant studies have shown that it can reduce the level of C-reactive protein (CRP) by reducing inflammatory responses, thereby lowering the risk of cardiovascular diseases such as heart disease and stroke. At the same time, it can increase the fluidity of cell membranes, reduce the level of low-density lipoprotein cholesterol (LDL) in the blood, and decrease the formation of atherosclerotic plaques in blood vessels, thereby preventing arrhythmias. It also has a certain alleviating effect on conditions such as hypertension. In addition, Palm Oil Oleic Acid 7070 plays a role in regulating glucose and lipid metabolism and has been regarded as a biomarker for reducing the risk of type 2 diabetes and coronary heart disease. For patients with fatty liver, changes in the content of palmitoleic acid in the body to some extent reflect the level of liver fat, suggesting that it may play a role in the treatment and regulation of fatty liver. In terms of drug formulations, it can also serve as a component of drug carriers, helping to improve the stability, solubility, and bioavailability of drugs, enabling drugs to reach the target site more efficiently and enhancing their efficacy.